Activity: Developer of self expandable stents for treating stenosis / blockages in bifurcated coronary arteries as well as heart attacks.
Key advantage: Novel and proprietary stent technology with demonstrated advantages over conventional products.
Milestones: Three CE Mark approvals. Comparative trial completed in June 2010, validated product’s potential superiority.